The positive regulatory developments and orphan drug designations for Lipella's leading drug candidates are likely to be viewed favorably by investors, potentially leading to a short-term increase in stock price. The successful completion of a Type C meeting with the FDA and the approval of an IND application are critical steps in drug development that can reduce investment risk and add credibility to the company's pipeline. The orphan drug designations may provide additional benefits such as market exclusivity, which can be a significant driver of value for a pharmaceutical company.